Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pelthos Therapeutics (PTHS) Non-Current Debt (2022 - 2025)

Pelthos Therapeutics has reported Non-Current Debt over the past 3 years, most recently at $131868.0 for Q2 2025.

  • For Q2 2025, Non-Current Debt changed 0.0% year-over-year to $131868.0; the TTM value through Jun 2025 reached $131868.0, changed 0.0%, while the annual FY2024 figure was $132000.0, 82.4% down from the prior year.
  • Non-Current Debt for Q2 2025 was $131868.0 at Pelthos Therapeutics, roughly flat from $131868.0 in the prior quarter.
  • Over five years, Non-Current Debt peaked at $750082.0 in Q4 2023 and troughed at $131868.0 in Q2 2024.
  • A 3-year average of $234925.7 and a median of $131868.0 in 2024 define the central range for Non-Current Debt.
  • Biggest five-year swings in Non-Current Debt: plummeted 82.4% in 2024 and later changed 0.0% in 2025.
  • Year by year, Non-Current Debt stood at $750082.0 in 2023, then plummeted by 82.4% to $132000.0 in 2024, then decreased by 0.1% to $131868.0 in 2025.
  • Business Quant data shows Non-Current Debt for PTHS at $131868.0 in Q2 2025, $131868.0 in Q1 2025, and $132000.0 in Q4 2024.